Literature DB >> 6329585

Simultaneous modeling of bopindolol kinetics and dynamics.

R Platzer, R L Galeazzi, W Niederberger, J Rosenthaler.   

Abstract

Bopindolol has beta-blocking effects for 96 hr despite a 4-hr t1/2. To investigate the concentration-effect relationship after single and repeated doses. 2-mg oral doses were given once and then daily for 13 days to six healthy subjects. In plasma, no unchanged drug, only the hydrolysis product of bopindolol (referred to as bopindolol concentration) was detectable or could be measured up to 24 hr. Chemical assay by HPLC and determination of total active beta-adrenoceptor blocking material by radioreceptor assay gave identical results. The t1/2 was 4 to 5 hr. Effects, measured as reduction in exercise-induced tachycardia (REIT) and as the isoproterenol dose ratio (DR - 1), were followed for 96 hr. The concentration of bopindolol in plasma (predicted with a one-compartment body model) could be related to the measured effects by classic effect models for 20 t1/2s. Parameter estimates for kinetic end effect models did not differ after single and repeated doses. With the parameters from the single-dose experiment, the time course of the plasma concentration and the effects after the multiple-dose experiment could be adequately predicted for 24 and 96 hr. A deep compartment, an active metabolite, or irreversible destruction of the receptor (accounting for the persistence of the effect) could be excluded. The "dissociation constant" of 100 pmol/l (from DR -1/concentration) and the minimal effective plasma concentration (from REIT/log concentration) of 1 pmol/l suggest that enough receptors are occupied at chemically unmeasurable levels in plasma to induce an effect. The "dissociation constant" determined in vivo is of the same order as that from in vitro radioligand studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329585     DOI: 10.1038/clpt.1984.130

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Effects of mental and physical stress on plasma catecholamine levels before and after beta-adrenoceptor blocker treatment.

Authors:  E Paran; L Neumann; N Cristal
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.

Authors:  D Holmes; E Nuesch; J M Houle; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.

Authors:  J Drewe; R Meier; U Timonen; M Thumshirn; J Munzer; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

4.  Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.

Authors:  P Francheteau; J L Steimer; C Dubray; D Lavene
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

5.  Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Authors:  R Lapka; T Sechser; V Rejholec; M Peterková; M Votavová
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.

Authors:  P Fitscha; W Meisner; B Tiso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.

Authors:  G P Carboni; A B Scardovi; M D'Ermo; P L Prati
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

9.  Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

10.  Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.

Authors:  W H Aellig; E Nüesch; G Engel; J Grevel; W Niederberger; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.